US FDA Approves Reformulated Ranitidine Tablets

Return to the Market

In November 2025, the U.S. Food and Drug Administration (US FDA) granted approval for reformulated ranitidine tablets, marking the return of this essential H₂ receptor antagonist to the U.S. market after a five-year hiatus. This decision follows rigorous safety evaluations and enhancements in manufacturing processes that ensure product quality throughout its shelf life.

Therapeutic Effectiveness and Updated Labeling

The newly approved formulation retains the same therapeutic effectiveness as previous versions, now accompanied by updated labeling that offers improved guidance on storage and handling.

Global Recognition of Ranitidine

WHO Essential Medicines List Inclusion

Coinciding with the US FDA’s approval, the World Health Organization (WHO) included ranitidine in its 24th Model List of Essential Medicines (EML), which features 523 medicines across various therapeutic categories. This inclusion underscores the ongoing significance of H₂ receptor antagonists in clinical practice and highlights ranitidine’s relevance, especially in resource-limited settings where effective and affordable treatment options are crucial for public health.

International Approvals

Earlier in 2025, both the Therapeutic Goods Administration (TGA) in Australia and the Ministry of Health in New Zealand approved the reintroduction of ranitidine into their respective pharmaceutical markets. These approvals were based on thorough reviews of manufacturing protocols and the implementation of enhanced quality assurance measures to ensure compliance with NDMA standards. This trend reflects a broader global movement towards evidence-based reassessment of ranitidine’s clinical utility.

Research Findings on Ranitidine and Cancer Risks

Multinational Cohort Study Results

A multinational cohort study involving over 1.18 million adults from 11 databases across Europe, North America, and Asia investigated potential cancer-related risks associated with ranitidine use. The study concluded that ranitidine does not increase overall cancer risk, with hazard ratios indicating no significant difference. Specifically, the AmbEMR database reported a hazard ratio of 1.00 (95% CI: 0.97–1.03), while the CUIMC database showed a 3% lower risk (HR 0.97; 95% CI: 0.87–1.08), demonstrating no measurable rise in cancer incidence compared to other H2 receptor antagonists.

Ranitidine: A Trusted Treatment Option

Clinical Applications

Since its introduction in 1981, ranitidine has been widely utilized to treat gastroesophageal reflux disease (GERD) and is one of the most prescribed medications worldwide for GERD and peptic ulcer disease. It is available in various forms, including oral and parenteral dosage forms such as tablets, capsules, oral syrup, and injectables.

Mechanism of Action

Ranitidine operates by inhibiting acid secretion through the blockade of histamine binding to the parietal cell H2 receptor, which prevents its stimulatory effects. This mechanism effectively reduces gastric acid secretion by limiting histamine’s influence and decreasing the response to other stimulatory agents. Furthermore, ranitidine has been noted for its favorable safety profile, often resulting in fewer adverse events, making it a more tolerable option for patients.

Conclusion

The US FDA’s approval of the reformulated ranitidine reinforces its clinical significance, affirming the medication’s ongoing role in evidence-based acid suppression therapy. Additionally, the retention of ranitidine on the WHO Essential Medicines List further supports its importance across diverse healthcare systems, particularly in regions where accessible and effective treatment options are essential.

References

1. U.S. Food and Drug Administration. (2025, November 24). FDA approves reformulated ranitidine following comprehensive safety review. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-reformulated-ranitidine-following-comprehensive-safety-review
2. World Health Organization. (2025). WHO Model List of Essential Medicines 2025 (24th list). WHO. https://www.who.int/publications/
3. New Zealand Government. (2025, January 30). Consent to the distribution of new medicines: Zantac (general sale) and Zantac (pharmacy only) (Notice No. 2025-go458). New Zealand Gazette. https://gazette.govt.nz/
4. Australian Government Department of Health and Aged Care, Therapeutic Goods Administration. (2025). Application under s. 23 to register a new medicine under s. 25 in the Australian Register of Therapeutic Goods: Zantac ranitidine 150 mg (as hydrochloride) tablets (Submission No. OM-2024-00299-1). https://www.tga.gov.au/
5. You SC, Seo SI, Falconer T, et al. Ranitidine Use and Incident Cancer in a Multinational Cohort. JAMA Netw Open. 2023;6(9):e2333495. Published 2023 Sep 5. doi:10.1001/jamanetworkopen.2023.33495
6. Morgan KA, Ahlawat R. Ranitidine. [Updated 2022 Dec 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532989/